I just ran across this Saphris® (asenapine) item at TradingMarkets.com, and while Merck is pitching it as a net-positive, its own disclosures make it neutral (at best), to slightly negative.
I trust Salmon will fill us in, here -- but here is a snippet:
. . . .Merck presented positive efficacy and safety data of Saphris for persistent negative symptoms of schizophrenia, thus supporting previous trial data. According to the results, over 52 weeks, treatment with Saphris significantly improved patients' negative symptoms compared to olanzapine on the 16-item Negative Symptom Assessment scale total score. However, dropout rates were higher for Saphris compared to patients on olanzapine and extrapyramidal symptoms were recorded for 24% of Saphris patients compared to only 10% in the olanzapine group. . . .
Paging Dr. Salmon. . . . um, I'm no mathematician, but that's more than two times the adverse events, compared to olanzapine arm. So-called "Extrapyramidal events" resemble Parkinson's disease, and include tremor of the limbs, and often appear with bradykinesia -- a greatly impeded ability to start and continue movements, and impaired ability to adjust the body's position. Yikes.